Calquence (Acalabrutinib), Astrazeneca’s bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
T-COVID is anticipated to provide clinical benefit to COVID-19 patients that are not yet hospitalized in the phase 1/2 clinical trial.
Novavax has purchased Praha Vaccines, a biologics manufacturer in the Czech Republic, to support mass production of its COVID-19 vaccine.
AB201, a potential protein-based treatment for blood clotting related to COVID-19, will be developed by ARCA Biopharma towards the clinic.
Wisconsin-based Waisman Biomanufacturing will produce the vaccine under development by Heat Biologics for the virus that causes COVID-19.
Patient enrollment in the phase 1/2 trial of NVX-CoV2373 has already started with preliminary phase 1 trial data expected in July of 2020.
Potential NantKWest COVID-19 therapy BM-AlloMSC will be tested in a phase 1b clinical trial with cell product from Be The Match BioTherapies.
Vaxart chose a lead oral COVID-19 vaccine candidate based on pre-clinical animal models and partnered with KindredBio for manufacturing.
Inovio COVID-19 vaccine INO-4800 induced robust neutralizing antibody and T cell immune responses in animal models, Nature publication shows.